Institute for Clinical and Translational Research , University of Wisconsin-Madison School of Medicine and Public Health , Madison , Wisconsin 53705 , United States.
J Proteome Res. 2019 Sep 6;18(9):3447-3460. doi: 10.1021/acs.jproteome.9b00342. Epub 2019 Aug 28.
Type II epithelial-mesenchymal transition (EMT) plays a vital role in airway injury, repair, and remodeling. Triggered by growth factors, such as transforming growth factor beta (TGFβ), EMT induced a biological process that converts epithelial cells into secretory mesenchymal cells with a substantially increased production of extracellular matrix (ECM) proteins. Epithelial cells are not professional secretory cells and produce few ECM proteins under normal conditions. The molecular mechanism underlying the transformation of the protein factory and secretory machinery during EMT is significant because ECM secretion is central to the pathogenesis of airway remodeling. Here we report that type II EMT upregulates the protein N-glycosylation of ECMs. The mechanism study reveals that the substantial increase in synthesis of ECM proteins in EMT activates the inositol-requiring protein 1 (IRE1α)-X-box-binding protein 1 (XBP1) axis of the unfolded protein response (UPR) coupled to the hexosamine biosynthesis pathway (HBP). These two pathways coordinately up-regulate the protein N-glycosylation of ECM proteins and increase ER folding capacity and ER-associated degradation (ERAD), which improve ER protein homeostasis and protect transitioned cells from proteotoxicity. Inhibition of the alternative splicing of XBP1 or protein N-glycosylation blocks ECM protein secretion, indicating the XBP1-HBP plays a prominent role in regulating the secretion of ECM proteins in the mesenchymal transition. Our data suggest that the activation of XBP1-HBP pathways and elevation of protein N-glycosylation is an adaptive response to maintain protein quality control and facilitate the secretion of ECM proteins during the mesenchymal transition. The components of the XBP1-HBP pathways may be therapeutic targets to prevent airway remodeling.
II 型上皮-间充质转化(EMT)在气道损伤、修复和重塑中起着至关重要的作用。EMT 是由生长因子(如转化生长因子β(TGFβ))触发的,它诱导一个生物学过程,将上皮细胞转化为具有大量细胞外基质(ECM)蛋白产生能力的分泌型间充质细胞。上皮细胞不是专业的分泌细胞,在正常情况下很少产生 ECM 蛋白。EMT 过程中蛋白工厂和分泌机制的转化的分子机制非常重要,因为 ECM 分泌是气道重塑发病机制的核心。在这里,我们报告 II 型 EMT 上调 ECM 的蛋白 N-糖基化。机制研究揭示,EMT 中 ECM 蛋白合成的大量增加激活了未折叠蛋白反应(UPR)的肌醇需求蛋白 1(IRE1α)-X 盒结合蛋白 1(XBP1)轴与己糖胺生物合成途径(HBP)偶联。这两条途径协同上调 ECM 蛋白的蛋白 N-糖基化,增加内质网折叠能力和内质网相关降解(ERAD),从而改善内质网蛋白的稳态并保护转化细胞免受毒性。XBP1 的选择性剪接或蛋白 N-糖基化的抑制会阻断 ECM 蛋白的分泌,表明 XBP1-HBP 在调节间充质转化中 ECM 蛋白的分泌中起着重要作用。我们的数据表明,XBP1-HBP 途径的激活和蛋白 N-糖基化的升高是维持蛋白质质量控制和促进间充质转化中 ECM 蛋白分泌的一种适应性反应。XBP1-HBP 途径的成分可能是预防气道重塑的治疗靶点。